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1 Introduction
In adult life, pituitary growth hormone (GH) se-
cretion is mainly controlled by the stimulatory
action of growth hormone releasing hormone
(GHRH) and by the inhibitory effect of somatos-
tatin (SRIH). Besides that, other factors seem to
be involved in the regulation of GH secretion.
Noradrenaline, dopamine (DA) and serotonine
have a stimulatory action on GH secretion. Acti-
vation of central nervous system (C. N. S.) chol-
inergic pathways enhances GH secretion and the
administration of gabaergic compounds has a
stimulatory effect on GH release. In rat, opioid
peptides have been reported to stimulate GH se-
cretion, and in man the administration of an
analogue of metenkefaline (FK 33 — 084) was ef-
fective in increasing serum GH concentrations [10,
18].
The regulation of GH secretion during fetal life
or in the perinatal period has been less extensively
studied. In the term fetus, cord blood GH concen-
trations are elevated. This condition has been at-
tributed to an immaturity of the hypothalamic
mechanisms controlling GH release [6]. This inter-
pretation seems to be supported by studies de-
scribing a paradoxical response of GH following
the administration of different substances such
as glucose [6], aminoacids [13], L-dopa [5], and
thyrotropin releasing hormone (TRH) [15].
In contrast, the pattern of GH response to the
administration of other compounds such as SRIH
[16], arginine [12] and insulin [3], indicates that
GH secretion is regulated by mechanisms similar
to those present in the adult life.
In the present study we have evaluated the effect
of the maternal administration of bromocriptine
on fetal and maternal serum GH concentrations.
In the adult, the administration of bromocriptine,
a DA agonist drug, has been found to have a
stimulatory effect on GH secretion [2].
2 Materials and methods
Eighty-seven normal, term pregnant women were
studied at parturition with their informed consent.
During labor 46 women, randomly selected, were
orally administered with 5 mg of bromocriptine,
whereas 41 received a placebo. Records were kept
detailing the time of bromocriptine or placebo
ingestion and the time of parturition. Maternal
and cord blood (CB) specimens were obtained
at parturition time from all mothers and their
neonates. Serum was separated by centrifugation
from red cells and stored at — 20 °C until assay.
During labor and delivery no adverse effects were
observed. The clinical course of neonates whose
mothers were treated with bromocriptine was un-
eventful.
Serum GH concentration was measured in all MS
and CB samples, except few whose volume was
not sufficient.
All samples, diluted 1 : 4 in phosphate buffer, were
measured in duplicate in the same assay and in
random order employing materials obtained by
Biodata (Milan, Italy). In this assay the cross
reactivity with human Placental Lactogen (hPL)
is 0.1%.
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For statistical evaluation, GH results in MS ob-
tained before bromocriptine and placebo ingestion
were assigned to two groups: basal treated and
basal control. GH results in MS specimens ob-
tained at parturition were assigned to two groups:
treated and control. Each of these two groups
was subdivided into 7 subgroups according to the
interval of time elapsed between bromocriptine or
placebo ingestion and parturition time. GH results
of neonates whose mothers were treated with bro-
mocriptine were assigned to one group, treated,
subdivided in 7 subgroups depending upon the
interval of time between drug assumption and
parturition time.
Similarly was done for GH concentrations of neo-
nates whose mothers were treated with placebo.
Statistical analysis was conducted using Student's
t test for unpaired samples and one way analysis
of variance (ANOVA). All values are expressed as
the mean + SE.
3 Results
Serum GH concentration in maternal serum: Before
treatment, serum GH concentration in pregnant
women receiving bromocriptine and placebo was
4.1 ± 0.1 ng/ml and 3.9 ± 0.1 ng/ml, respectively
(t test, NS).
At parturition, in control subgroups serum GH
concentration averaged between 3.6 and 4.7 ng/
ml. These values were not significantly different
(ANOVA test) from those observed in mothers
administered with bromocriptine. In these sub-
jects, serum GH concentration fluctuated between
3.5 and 4.5 ng/ml (table I).
Serum GH concentration in cord blood: In CB
samples of neonates whose mothers were treated
with placebo, serum GH concentrations were not
different (ANOVA test) from those measured in
neonates whose mothers received bromocriptine
(figure 1).
In both groups, control and treated, cord blood
GH concentrations were significantly higher than
the corresponding maternal values, p < 0.001 (t
test).
4 Discussion
The participation of the dopaminergic pathways
in the control of GH release has been clearly
documented in man [18]. It is well known that DA
agonist drug administration induces an increase of
serum GH concentration [10]. In healthy adult
subjects bromocriptine administration induces a
rapid increase of GH secretion whereas in acrome-
galic patients significantly lowers serum GH con-
centrations [2].
During the perinatal period the role of DA in the
control of GH secretion has been poorly investi-
gated.



















Control 4.7 ± 0.4b 3.7 ± 0.1 3.7 ± 0.2 3.7 ± 0.4 3.8 ± 0.4 4.1 ± 0.3 3.6
2C 8 9 5 6 7 1
Treated 4.3 ± 0.5 4.0 ± 0.3 4.4 ± 0.4 3.5 ± 0.2 3.5 ± 0.2 4.0 ± 0.3 4.5 ± 0.6
6 7 7 9 9 6 2
a) The range of time (minutes) elapsed between placebo or bromocriptine administration and maternal blood
sampling.
b) Mean ± SE.
c) Number of subjects in each subgroup.
No significant difference was observed between serum GH concentration in placebo and bromocriptine treated
mothers (ANOVA Test).
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Figure 1. Cord blood (CB) GH concentration in neonates whose mothers received placebo (ΙΙΠΠΠΠ3) and bromocriptine
(ι ι) at different time periods after treatment. The bars represent the mean values and the brackets the SE. The
numbers in parenthesis indicate the number of subjects in each group. No difference (ANOVA test) was observed
in CB GH concentration between placebo and bromocriptine groups.
In the neonate, a paradoxical suppression of GH
secretion has been observed after the administra-
tion of L-dopa [5]. In the ovine species, the admin-
istration of DA agonist drug induces a decrement
of serum GH concentration both during adult [4]
as well fetal and neonatal life [8].
In fetal and neonatal monkey, as in adult, the
administration of L-dopa induces an increase of
serum GH concentrations [6].
In the present study we have observed that the
administration of bromocriptine to the mother
does not induce any change of fetal serum GH
concentrations. The lack of any effect of bromo-
criptine administration on fetal GH secretion does
not seem to be related nor to an absent transfer
of the drug through the placenta neither to an
insufficient dose since we have observed that in
newborns whose mothers received bromocriptine
cord blood prolactin (PRL) concentrations were
significantly lower than in newborns of control
mothers [17].
Long term treatment with bromocriptine of an
acromegalic patient througout pregnancy did not
induce any change of fetal serum GH concentra-
tions [1]. These findings are in agreement with
the observation that maternal administration of
metoclopramide, a dopaminergic receptor block-
ing drug, did not modify cord blood GH concen-
trations (RoTi, unpublished data).
Thus it is likely that the absent action of bromo-
criptine on fetal GH secretion might be due to a
lack of activation of DA receptors at the hypotha-
lamic and/or pituitary level.
The administration of bromocriptine, as well, did
not induce any change in maternal serum GH
concentrations. This finding has been previously
reported in an acromegalic pregnant woman
chronically treated with bromocriptine [1], These
results are in agreement with a previous observa-
tion from our laboratory [11] reporting that the
administration of metoclopramide to parturient
women did not induce any change of serum GH
concentrations.
During late pregnancy, it has been reported an
absent or blunted serum GH surge following se-
cretory stimuli such as insulin induced hypoglyce-
mia [9] and arginine infusion [21]. The increased
serum concentrations of hPL [7], corticosteroids
[4] and progestins [20] have been indicated as
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possible hormonal factors responsible for the ab-
sent GH response to insulin induced hypoglyc-
emia.
Finally the hyperprolactinemic state both in ma-
ternal and fetal compartments might explain the
absent GH response to bromocriptine. Recently
it has been reported that in hyperprolactinemic
women with pituitary microadenoma the adminis-
tration of levo-DOPA and bromocriptine failed
to stimulate GH secretion. This finding has been
related to an impaired hypothalamic GHRH se-
cretion or to decreased pituitary sensitivity to
GHRH since L-Dopa and bromocriptine seem to
act on GH release via GHRH [19].
In conclusion the present study suggests that in
contrast to adult normal subjects bromocriptine
administration does not enhance fetal and ma-
ternal serum GH levels.
Summary
To investigate the role of dopaminergic pathways on the
control of growth hormone (GH) secretion, bromocrip-
tine (BMC), a dopamine agonist drug, was orally ad-
ministered at the dose of 5 mg to 46 pregnant women
during labor whereas 41 received placebo. Maternal
blood was obtained before drug administration and at
delivery. Cord blood was obtained at delivery. Follow-
ing the interval of time elapsed between BMC or placebo
ingestion and parturition, maternal and cord blood sam-
Keywords: Bromocriptine, fetal growth hormone.
pies were divided in 7 groups for statistical analysis.
Cord blood GH resulted significantly higher than the
corresponding maternal value (p < 0.001). No signifi-
cant change in GH values was observed nor in samples
of mothers treated with BMC compared to mothers
treated with placebo neither in cord blood samples of
the corresponding neonates. These findings indicate that
BMC administration does not modify GH secretion in
the term fetus.
Zusammenfassung
Dopaminerge Regulation der fetalen Wachstumshormon-
Sekretion: Studie mit Verabreichung von Bromokriptin an
die Mutter
Um die dopaminerge Wirkung auf die Sekretion des
Wachstumshormons (STH) zu beurteilen, wurde 46
schwangeren Frauen 5mg Bromokriptin, ein dopami-
nerges Medikament, p. o. verabreicht, während weitere
41 Frauen mit Placebo behandelt wurden. Blutproben
wurden vor der Verabreichung des Bromokriptin und
zum Zeitpunkt der Geburt abgenommen. Proben aus
der Nabelschnur wurden nach der Geburt gewonnen.
Zur statistischen Beurteilung der Werte wurden die Pro-
ben aus dem mütterlichen und fetalen Blut in 7 Gruppen
unterteilt, und zwar je nach dem zeitlichen Intervall, das
zwischen der Verabreichung des Medikamentes oder des
Placebos und der Geburt lag. Das STH des Nabel-
schnurblutes ergab bei allen Neugeborenen eindeutig
erhöhte Werte (p < 0,001) im Vergleich zum mütter-
lichen Blut. Bei einem Vergleich zwischen dem Blut von
Müttern, die mit Bromokriptin, und solchen, die mit
Placebo behandelt wurden, sowie bei Vergleichen des
Nabelschnurblutes der entsprechenden Neugeborenen
wurde kein signifikanter Unterschied bezüglich des STH
festgestellt. Diese Ergebnisse deuten an, daß Bromokrip-
tin die Sekretion des Wachstumshormons des reifen Neu-
geborenen nicht beeinflußt.
Schlüsselwörter: Bromokriptin, fetales Wachstumshormon.
Resume
Regulation dopaminergique de la secretion de l'hormone
de croissance ftetale: etude avec administration maternelle
de bromocriptine
Afin d'explorer le röle des voies dopaminergiques sur le
controle de la secretion de l'hormone de croissance
(GH), on a donne per os de la bromocriptine (BMC),
medicament agoniste de la dopamine, a la dose de 5 mg,
ä 46 femmes enceintes, pendant le travail, tandis que 41
femmes prenaient un placebo. Du sang maternel a ete
preleve avant la prise medicamenteuse et a 1'accouche-
ment. On a preleve du sang au cordon lors de Faccouche-
ment. En fonction de l'intervalle de temps qui s'est
ecoule entre la prise de BMC ou du placebo et Faccou-
Mots-cles: Bromocriptine, hormone de croissance foetale (GH).
chement, les prelevements sanguins maternels et du cor-
don ont ete divises en 7 groupes pour 1'analyse statisti-
que. Les resultats montrent que les valeurs de GH au
sang du cordon etaient significativement plus elevees
que les valeurs maternelles correspondantes (p < 0,001).
On n'a pas observe de modifications significatives des
valeurs de GH ni dans les prelevements de meres traitees
par BMC en comparaison avec les meres avec placebo
ni dans les prelevements au sang du cordon chez les
nourrissons correspondants. Ces resultats indiquent que
administration de BMC ne modifie pas la secretion de
GH chez le foetus a terme.
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